Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma

Table 1 Perfusion parameters in PR and SD group (mean ± SD)

	PR			SD
n = 14	Pre-treatment	Post-treatment	P value	Pre-treatment	Post-treatment	P value
HBF (mL/min per 100 mL)	294.594 ± 162.104	203.941 ± 147.717	0.096	133.277 ± 111.124	205.580 ± 217.101	0.054
HBV (mL/100 mL)	37.569 ± 19.818	19.252 ± 11.847	0.001	14.097 ± 4.276	21.558 ± 21.085	0.220
MTT (s)	10.385 ± 4.747	10.687 ± 2.132	0.637	14.097 ± 4.276	12.235 ± 4.276	0.421
PS (mL/min per 100 mL)	20.066 ± 19.398	19.997 ± 22.516	0.638	27.357 ± 21.960	22.504 ± 18.439	0.310
HAF (%)	63.671 ± 20.218	38.154 ± 22.357	0.030	42.343 ± 14.025	33.793 ± 18.575	0.248
HAP (mL/min/100 mL)	201.857 ± 145.608	57.266 ± 33.537	0.001	62.621 ± 65.274	78.230 ± 76.442	0.172
PVP (mL/min/100 mL)	92.590 ± 69.771	146.681 ± 144.414	0.330	70.664 ± 50.880	127.349 ± 167.413	0.054

Table 2 Perfusion parameters in PD group (mean ± SD)

PD (n = 10)	Pre-treatment	Post-treatment	P value
HBF (mL/min per 100 mL)	178.508 ± 63.650	263.828 ± 91.731	0.005
HBV (mL/100 mL)	28.101 ± 26.862	29.978 ± 9.261	0.385
MTT (S)	9.336 ± 2.517	10.001 ± 2.457	0.798
PS (mL/min/100 mL)	33.103 ± 3.784	26.384 ± 10.544	0.092
HAF (%)	45.856 ± 41.332	69.628 ± 30.126	0.012
HAP (mL/min per 100 mL)	32.686 ± 7.145	94.200 ± 55.928	0.005
PVP (mL/min per 100 mL)	19.820 ± 5.546	33.480 ± 8.765	0.035